FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W172020009> ?p ?o ?g. }

• W172020009 endingPage "51" @default.
• W172020009 startingPage "45" @default.
• W172020009 abstract "Idiopathic rhinitis without eosinophilia is a group of frequently observed diseases, the aetiopathogenesis of which is not yet well known. One of the most disturbing symptoms for patients within this disease group is nasal hypersecretion. Although many different treatments have been tried for hypersecretion, nasal topical drugs form the basis of any such therapy today. Ipratropium bromide (IB) is a drug offirst choice in nasal hypersecretion therapy. It displays a parasympatholytic effect in topical use and antagonizes acetylcholine transport in efferent parasympathetic nerves, thus decreasing submucosal gland secretion, which is the cause of hypersecretion. Botulinum toxin type A (BTX-A) is among the alternative treatment choices that is increasingly used in symptomatic treatment of nasal hypersecretion. Our study was planned with the aim of comparing the effect of these two groups of drugs on nasal hypersecretion. Thirty-eight patients who were diagnosed with idiopathic rhinitis without eosinophilia were included in the study and were divided in 3 different groups: In the first group, a total of 10 units of BTX-A were injected into both nasal cavities. In the second group, 3x2 IB was injected into both nasal cavities for 4 weeks. The third group received intranasal physiologic saline as placebo. The patients were evaluated in terms of nasal hypersecretion with visual analogue scale prior to the treatment and at weeks 1, 2, 4, 8, and 12 during the follow-up period. Throughout the 8 weeks follow-up period, the patient complaints displayed a 41.2% decrease in the group that received BTX-A and a 61.4% decrease in the group which received IB, while no change was observed in the control group. Both drug groups were well tolerated by the patients, with no serious adverse or systemic effects. As a result, while IB and BTX-A differ in terms of method of application, they display a similar degree and duration of efficiency in hypersecretion therapy." @default.
• W172020009 created "2016-06-24" @default.
• W172020009 creator A5017842773 @default.
• W172020009 creator A5037721585 @default.
• W172020009 creator A5043318895 @default.
• W172020009 creator A5067932670 @default.
• W172020009 creator A5082523574 @default.
• W172020009 creator A5086359995 @default.
• W172020009 creator A5090970381 @default.
• W172020009 date "2008-03-01" @default.
• W172020009 modified "2023-10-18" @default.
• W172020009 title "Investigation of the effects of intranasal botulinum toxin type A and ipratropium bromide nasal spray on nasal hypersecretion in idiopathic rhinitis without eosinophilia" @default.
• W172020009 cites W1515292920 @default.
• W172020009 cites W1975109912 @default.
• W172020009 cites W1975304390 @default.
• W172020009 cites W1977033467 @default.
• W172020009 cites W1995613822 @default.
• W172020009 cites W2019659005 @default.
• W172020009 cites W2021206454 @default.
• W172020009 cites W2024481694 @default.
• W172020009 cites W2029424959 @default.
• W172020009 cites W2029494854 @default.
• W172020009 cites W2035252725 @default.
• W172020009 cites W2041823607 @default.
• W172020009 cites W2042608343 @default.
• W172020009 cites W2047800887 @default.
• W172020009 cites W2068650943 @default.
• W172020009 cites W2080281818 @default.
• W172020009 cites W2080843301 @default.
• W172020009 cites W2086964698 @default.
• W172020009 cites W2087753663 @default.
• W172020009 cites W2090461672 @default.
• W172020009 cites W2095363104 @default.
• W172020009 cites W2140009440 @default.
• W172020009 cites W2153798544 @default.
• W172020009 cites W2396142410 @default.
• W172020009 cites W2397741631 @default.
• W172020009 cites W2416651075 @default.
• W172020009 cites W2419414878 @default.
• W172020009 cites W400034079 @default.
• W172020009 cites W583032318 @default.
• W172020009 cites W2409445263 @default.
• W172020009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18444492" @default.
• W172020009 hasPublicationYear "2008" @default.
• W172020009 type Work @default.
• W172020009 sameAs 172020009 @default.
• W172020009 citedByCount "12" @default.
• W172020009 countsByYear W1720200092013 @default.
• W172020009 countsByYear W1720200092014 @default.
• W172020009 countsByYear W1720200092015 @default.
• W172020009 countsByYear W1720200092016 @default.
• W172020009 countsByYear W1720200092017 @default.
• W172020009 countsByYear W1720200092021 @default.
• W172020009 crossrefType "journal-article" @default.
• W172020009 hasAuthorship W172020009A5017842773 @default.
• W172020009 hasAuthorship W172020009A5037721585 @default.
• W172020009 hasAuthorship W172020009A5043318895 @default.
• W172020009 hasAuthorship W172020009A5067932670 @default.
• W172020009 hasAuthorship W172020009A5082523574 @default.
• W172020009 hasAuthorship W172020009A5086359995 @default.
• W172020009 hasAuthorship W172020009A5090970381 @default.
• W172020009 hasConcept C126322002 @default.
• W172020009 hasConcept C141071460 @default.
• W172020009 hasConcept C142724271 @default.
• W172020009 hasConcept C203014093 @default.
• W172020009 hasConcept C204787440 @default.
• W172020009 hasConcept C207480886 @default.
• W172020009 hasConcept C27081682 @default.
• W172020009 hasConcept C2776042228 @default.
• W172020009 hasConcept C2777129736 @default.
• W172020009 hasConcept C2778311950 @default.
• W172020009 hasConcept C2779279117 @default.
• W172020009 hasConcept C2780532441 @default.
• W172020009 hasConcept C2780973058 @default.
• W172020009 hasConcept C2781018748 @default.
• W172020009 hasConcept C42219234 @default.
• W172020009 hasConcept C59377437 @default.
• W172020009 hasConcept C71924100 @default.
• W172020009 hasConcept C85663871 @default.
• W172020009 hasConceptScore W172020009C126322002 @default.
• W172020009 hasConceptScore W172020009C141071460 @default.
• W172020009 hasConceptScore W172020009C142724271 @default.
• W172020009 hasConceptScore W172020009C203014093 @default.
• W172020009 hasConceptScore W172020009C204787440 @default.
• W172020009 hasConceptScore W172020009C207480886 @default.
• W172020009 hasConceptScore W172020009C27081682 @default.
• W172020009 hasConceptScore W172020009C2776042228 @default.
• W172020009 hasConceptScore W172020009C2777129736 @default.
• W172020009 hasConceptScore W172020009C2778311950 @default.
• W172020009 hasConceptScore W172020009C2779279117 @default.
• W172020009 hasConceptScore W172020009C2780532441 @default.
• W172020009 hasConceptScore W172020009C2780973058 @default.
• W172020009 hasConceptScore W172020009C2781018748 @default.
• W172020009 hasConceptScore W172020009C42219234 @default.
• W172020009 hasConceptScore W172020009C59377437 @default.
• W172020009 hasConceptScore W172020009C71924100 @default.
• W172020009 hasConceptScore W172020009C85663871 @default.
• W172020009 hasIssue "1" @default.

• next